weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)
Post on 13-Sep-2014
1.669 views
DESCRIPTION
Free slide show on weight gain, diabetes and metabolic problems in those taking atypical antipsychotic medication in schizophrenia, bipolar disorder and related conditions. Image credits retained by original authors. Please give correct acknolwedgements if you present any material from here.TRANSCRIPT
![Page 1: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/1.jpg)
Alex J Mitchell www.psycho-oncology.infoUniversity of Leicester (UK)
AcknowledgementsDavy Vancampfort, BelgiumMarc De Hert, Belgium
Weight Gain, Diabetes and Metabolic Problems
in Patients prescribed Atypical Antipsychotics
Online Information Oct 2011. Only use these slides for personal use and/or with credit to the author
![Page 2: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/2.jpg)
I. Background
![Page 3: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/3.jpg)
What are Severe Mental Health problems?
These usually include
Schizophrenia and related disorders
Bipolar Affective Disorder (prev known as manic-depression)
Severe depression
These conditions are sometimes collectively called “SMI” and tend to be the ones where are antipsychotic is prescribed
![Page 4: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/4.jpg)
Is there Accelerated mortality in SMI?
Yes, there is premature mortality by 20 years on average
This “mortality gap” has been increasing, as shown over….
![Page 5: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/5.jpg)
Schizophrenia –Standardized Mortality Ratio
Pooled estimate=2.50 (95% CI=2.18-2.83)
>
>>>
Saha Arch Gen Psychiatry. 2007 Oct;64(10):1123-31.
![Page 6: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/6.jpg)
*Controlling for age at first diagnosis and years of follow-up**Standardised by the sex and age distribution of the patients Data from Osby et al 2000
Mortality trends in Stockholm County 1976–79 to 1990–95, cardiovascular causes of death
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1976–79 1980–85 1986–89 1990–95
Dea
ths/
100,
000
197
6–79
per
iod
of re
fere
nce Patients with schizophrenia*
General population**
![Page 7: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/7.jpg)
Cardiovascular disease is primary cause of death in persons with mental illness*
*Average data from 1996–2000
Perc
enta
ge o
f dea
ths
50
40
20
10
0
30
Heart disease Cancer Cerebrovascular Chronic respiratoryDiabetes Influenza/pneumoniaAccidents Suicide
MO OK RI TX UT VA
Data From Colton & Manderscheid 2006
![Page 8: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/8.jpg)
What is the Concern Re Obesity in the Popn?In 195025% US adults were overweight (BMI > 25)
In 200525% were obese (BMI > 30)
In 199825% of children were overweight
By 2012Only 25% of the US population will not be overweight
BMI = weight / height squared
![Page 9: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/9.jpg)
![Page 10: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/10.jpg)
![Page 11: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/11.jpg)
Obesity increases the risk of disease
Willet et al. Guidelines for Healthy Weight (1999) NEJM 341, 427 - 433
![Page 12: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/12.jpg)
Which Risk Factors Are Important?
For cardiovascular disease and general mortality…
Blood pressure (BP)
Smoking
Inactivity (fitness)
Weight / obesity
Cholesterol / lipids
![Page 13: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/13.jpg)
Ranking of selected risk factors: 6 leading causes of death by income group, estimates for 2004
Percentage of total (total: 1.53 billion)World Health Organization. http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.htm
![Page 14: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/14.jpg)
The following are important for diabetes
IFG BP
WaistHDL TG≥ 102 cm or 40 inches
(m)≥ 88 cm or 36 inches(f)
≥150 mg/dl< 40 mg/dL (m)< 50 mg/dL (f)
≥ 130/85 mmHg≥ 6.1 mmol/L (110 mg/dl).
TG = triglycerides; IFG = impaired fasting glucose; HDL = high density lipids
Collectively known as “metabolic syndrome” (when 3x are present)
![Page 15: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/15.jpg)
How Many Antipsychotics are prescribed?About 6million prescriptions in the UK per year
Perhaps to 0.5 million people in the UK annually (estimated)
Globally they generate about 20billion per year for the pharmaceutical industry
They are prescribed for several mental health conditions
About 15% are given to the under 18’s
![Page 16: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/16.jpg)
$0$2
$4$6$8
$10$12
$14$16
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2006(est.)
$ Bi
llion
s
Source: IMS; Robert Rosenheck MD
Global Antipsychotic Market Sales(MAT Q1 by Yr)
![Page 17: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/17.jpg)
Most common uses of atypical antipsychoticsOff label use accounts for ~ 1/3 of prescriptions
![Page 18: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/18.jpg)
![Page 19: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/19.jpg)
II. Weight, diabetes complications of Atypicals
The following are of high concern in SMI (next slide)
![Page 20: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/20.jpg)
IFGBP
Waist
HDL
TG≥ 102 cm or 40 inches
(m)≥ 88 cm or 36 inches(f)
≥150 mg/dl
< 40 mg/dL (m)< 50 mg/dL (f)
–≥ 130/85 mmHg≥ 6.1 mmol/L (110 mg/dl).
Diab
Smoking
![Page 21: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/21.jpg)
Prevalence of diabetes in schizophrenia compared to general population
8.6% diabetes; n=415 Slide thanks to De Hert et al 2006
15
Age group (years)
General population Patients
15–25 25–35 35–45 45–55 55–650
5
10
20
25
30
0.42.0 0.9 1.1
6.1
25.0
5.8
Prev
alen
ce o
f dia
bete
s (%
)
3.2 2.4
12.7
![Page 22: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/22.jpg)
Bipolar comparison study – prevalence of metabolic disturbances
72.359.8
71.6
17.029.3
22.1
10.7 10.9 6.4
010
20304050
607080
90100
Bipolar(n=112)
Schizoaffective(n=92)
Schizophrenia(n=503)
Prev
alen
ce o
f met
abol
icdi
stur
banc
es (%
)
Normal glucose values (n=496) Pre-diabetes (n=157) Diabetes (n=54)
van Winkel et al 2008
![Page 23: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/23.jpg)
BMI change after 52 weeks of olanzapine in bipolar patients
Image Credit: Hennen (2004)
![Page 24: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/24.jpg)
Antipsychotic-induced diabetes mellitus..warning in 2003
October 20, 2003FDA warns diabetes and antipsychotic medicationsFDA to require diabetes warning on antipsychotics
In a series of letters delivered in mid-September, the US FDA disclosed to makers of atypical antipsychotic medications that it will require each drug maker to re-label its product to include warnings regarding risk of hyperglycaemia and diabetes mellitus
![Page 25: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/25.jpg)
About the CATIE Study of Atypicals…..
• Non-industry sponsored. • 1493 patients.• 18 month double blind.• Olanzapine, quetiapine, risperidone, ziprasidone &
perphenazine74% discontinued before 18 months, median 4.6
months. Olanzapine 9.2 months
Metabolic problems much greater versus general population
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209–1223
![Page 26: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/26.jpg)
26
Comparison of Metabolic Syndrome and Individual Criterion Prevalence: Fasting CATIE vs Matched NHANES III Subjects
Men WomenCATIE
(%)(N=509)
NHANES (%)(N=509) P CATIE (%)
(N=180)
NHANES III (%)
(N=180)P
Metabolic syndrome prevalence 36.0 19.7 .0001 51.6 25.1 .0001
Waist circumference criterion 35.5 24.8 .0001 76.3 57.0 .0001
Triglyceride criterion 50.7 32.1 .0001 42.2 19.6 .0001
HDL criterion 48.9 31.9 .0001 63.3 36.3 .0001
BP criterion 47.2 31.1 .0001 46.9 26.8 .0001
Glucose criterion 14.1 14.2 .9635 21.7 11.2 .0075
CATIE = Clinical Antipsychotic Trials of Intervention Effectiveness; NHANES = National Health and Nutrition Examination Survey.McEvoy JP et al. Schizophr Res. 2005;80:19-32.
![Page 27: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/27.jpg)
CATIE: rates of pharmacological interventions for abnormal blood pressure, lipids and glucose
Nasrallah et al 2006
n=1488 n=685 n=690
Patie
nts
(%)
n=481 n=300 n=75 n=34 n=471 n=421
33.2
10.9
68.362.4
45.3
89.4
0
20
40
60
80
100
Hypertension Diabetes Dyslipidaemia
Prevalence Lack of medical intervention
![Page 28: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/28.jpg)
But not everyone gains weight….
![Page 29: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/29.jpg)
20% do not gain weight over 2yrs of Olanzapine Treatment
Data from Basson, Kinon JCP
![Page 30: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/30.jpg)
Weight gain begins early, typically plateaus
![Page 31: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/31.jpg)
Weight Gain 3yrs of Olanzapine (n=573) vs Haloperidol (n=103) Treatment
Data from Kinon (2001) J Clin Psychiatry 62:92-100; Image Credit: JCP / Physicians Press
7kg
![Page 32: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/32.jpg)
Weight Gain During 3yrs of Olanzapine (n=573) by baseline weight
9.5kg
7kg
3kg
Data from Kinon (2001) J Clin Psychiatry 62:92-100; Image Credit: JCP / Physicians Press
![Page 33: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/33.jpg)
Weight gain seen in bipolar disorder too
![Page 34: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/34.jpg)
Weight Gain During 32 weeks of Olanzapine (n=948) by baseline weight in bipolar disorder
8kg
Lipkovich Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine. J Clin Psychopharm 2006;26:316-320
6kg
4.5kg
![Page 35: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/35.jpg)
Weight gain highest in drug-naive patients
![Page 36: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/36.jpg)
36
2-Year Weight Gain in First-Episode Schizophrenia: Effect of Type of Analysis
Zipursky RB et al. Br J Psychiatry. 2005;187:537-543. OLZ = olanzapine HAL = Haloperidol
18
16
14
12
10
8
6
4
2
00 10 20 30 40 50 60 70 80 90 100 110
OLZ( Yr 1): n=35OLZ (Yr 2): n=13
HAL (Yr 1): n=47HAL (Yr 2): n=28
15.4 kg
7.5 kg
Week of Therapy
![Page 37: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/37.jpg)
Haloperidol Amisulpride OlanzapineQuetiapine Ziprasidone
0102030405060708090
Wei
ght g
ain
>7%
from
ba
selin
e (%
)
p=0.053*
5363
86%
65
37
02468
10121416
7.3
9.7
13.9
4.8
10.5
p<0.0001*
Wei
ght c
hang
e fr
om
base
line
(kg)
EUFEST – randomised controlled 12-month trial (n=498)
Kahn RS et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet . 2008 Mar 29 ; 371(9618):1085-97
![Page 38: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/38.jpg)
CAFE study – weight and related measures in first-episode schizophrenia
McEvoy et al 2007
5.7
Weight change
*
*
7.0
11.0
3.7 4.0
6.6
0
2
4
6
8
10
12
Week 12 Week 52
Leas
t squ
ares
mea
n ch
ange
(kg)
Risperidone (n=133)Quetiapine (n=134)Olanzapine (n=133)
0
20
40
60
80
100
Week 12 Week 52Pe
rcen
tage
of
patie
nts
**
**80.0
50.058.060.0
29.0 32.0
Weight gain 7%#
![Page 39: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/39.jpg)
Summary of Metabolic Complications
We have summarized all existing data of studies measuring metabolic problems in three groups:
Established schizophrenia
Vs early (first epsiode schizophrenia)
Vs unmedicated patients with schizophrenia
![Page 40: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/40.jpg)
0.101
0.2660.243
0.169
0.051
0.204
0.402
0.027
0.099
0.22
0.304
0.196
0.052
0.219
0.468
0.119
0.33
0.49
0.390.4
0.2
0.43
0.54
0.11
0
0.1
0.2
0.3
0.4
0.5
0.6
MetS Waist (m > 102 f >88)
BP Triglycerides >150 mg/dl
IFG HDL (M <40mg/dl,F <50 mg/dl)
Smoking Diabetes
Unmedicated
First Episode
Schizophrenia
![Page 41: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/41.jpg)
….and against general population rates?
![Page 42: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/42.jpg)
0.101
0.2660.243
0.169
0.051
0.204
0.402
0.027
0.099
0.22
0.304
0.196
0.052
0.219
0.468
0.119
0.33
0.49
0.39 0.4
0.2
0.43
0.54
0.11
0.25 0.25
0.3 0.3
0.15
0.3
0.2
0.04
0
0.1
0.2
0.3
0.4
0.5
0.6
MetS (3 of 5) Waist (m >102f>88)
BP (>130/85) Triglycerides(>150 mg/dl)
IFG (6.1 mmol/L or110 mg/dl)
HDL (M<40mg/dl,F<50 mg/dl)
Smoking Diabetes
Unmedicated
First Episode
Schizophrenia
General Population
![Page 43: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/43.jpg)
…are patients monitored for these problems?Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De
Hert M.
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.
Psychol Med. 2011 Aug 10:1-23. [Epub ahead of print]
![Page 44: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/44.jpg)
Psychol Med. 2011 Aug 10:1-23. [Epub ahead of print]
![Page 45: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/45.jpg)
Can metabolic complications be avoided?
Yes by….
• By switching to a weight sparing antipsychotic
• By giving lifestyle advice and assistance
• By adding in weight loss medication (early or late)
• By avoiding weight gaining antipsychotics (only a few exist)
![Page 46: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/46.jpg)
Estimated Weight Change (lb) After Switch to Ziprasidone†
†Repeated measures analysis
Conventionals Olanzapine Risperidone-25
-20
-15
-10
-5
0
5
LS M
ean
Cha
nge,
lb
49 53 584540363227231914106
Weeks
*
***
***
**
**
***
*P<0.05 **P<0.001***P<0.0001
Switched from
Improvem
ent
Presented at APA 2004, New York, NY
![Page 47: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/47.jpg)
Alvarez-Jiménez– lifestyle in Unmedicated 1st Episode (10-14 sessions over 3mo)
Alvarez-Jiménez M J Clin Psychiatry. 2006 Aug;67(8):1253-60. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.
![Page 48: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/48.jpg)
Chen – Metformin after 3mo of Olanzapine Rx
50
29.2
50
33.3
25 25
41.7
29.2
45.9
29.2
16.7
20.8
41.7
29.2
41.7
29.2
16.7
12.5
25 25
29.2
20.8
12.6 12.5
0
10
20
30
40
50
60
Metabolic syndrome Abdominal obesity Fastinghypertriglyceridemia
Low fasting HDL High blood pressure High fasting glucose
Baseline
2 weeks
4 weeks
8 weeks
Chen et al (2008) Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32 (2008) 925–931
![Page 49: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/49.jpg)
Metformin Coprescription at start of Olanzapine
Wu et al Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: Am J Psychiatry 2008; 165:352–358
1.491.37
0.45 0.41
2.131.86
0.59 0.53
5.14
1.87 1.92
0.53
6.87
1.9
2.26
0.54
0
1
2
3
4
5
6
7
8
Kg_Olan+Plb Kg_Olan+Met BMI_Olan+Plb BMI_Olan+Met
Week 2
Week 4
Week 8
Week 12
![Page 50: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/50.jpg)
Metformin in patients on antipsychotic drugs: a systematic review and meta-analysis
Bjorkhem-Bergman Journal of Psychopharmacology 2010; 25(3) 299–305
![Page 51: Weight diabetes and metabolic problems in patients taking atypical antipsychotics (ajmitchell)](https://reader033.vdocuments.mx/reader033/viewer/2022061104/5413f80f8d7f72be698b47a1/html5/thumbnails/51.jpg)
Alex J Mitchell www.psycho-oncology.infoUniversity of Leicester (UK)
AcknowledgementsDavy Vancampfort, BelgiumMarc De Hert, Belgium
Weight Gain, Diabetes and Metabolic Problems
in Patients prescribed Atypical Antipsychotics
Online Information Oct 2011